INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 204 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2015. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $6,741,000 | +86.7% | 54,400 | 0.0% | 0.21% | +47.9% |
| Q3 2019 | $3,610,000 | -9.3% | 54,400 | +8.8% | 0.14% | 0.0% |
| Q2 2019 | $3,979,000 | +178.8% | 50,000 | +400.0% | 0.14% | +35.8% |
| Q2 2016 | $1,427,000 | +11.1% | 10,000 | 0.0% | 0.11% | -1.9% |
| Q1 2016 | $1,285,000 | -44.5% | 10,000 | -35.5% | 0.11% | -38.3% |
| Q4 2015 | $2,315,000 | -57.1% | 15,500 | -52.3% | 0.18% | -60.0% |
| Q3 2015 | $5,390,000 | -31.3% | 32,500 | 0.0% | 0.44% | -23.6% |
| Q2 2015 | $7,845,000 | -22.7% | 32,500 | -9.7% | 0.57% | -39.7% |
| Q1 2015 | $10,153,000 | +296.9% | 36,000 | +119.5% | 0.95% | +217.7% |
| Q4 2014 | $2,558,000 | -28.4% | 16,400 | +8.6% | 0.30% | -45.9% |
| Q3 2014 | $3,574,000 | +0.0% | 15,100 | 0.0% | 0.55% | -13.7% |
| Q2 2014 | $3,573,000 | -16.7% | 15,100 | +16.2% | 0.64% | -35.2% |
| Q1 2014 | $4,287,000 | +280.4% | 13,000 | -21.2% | 0.99% | +145.4% |
| Q4 2013 | $1,127,000 | – | 16,500 | – | 0.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |